E
SciSparc Ltd. SPRC
$0.2794 -$0.0066-2.31% NASDAQ
Recommendation
Prev Close
$0.286
Volume
173,973
Avg Vol (90D)
7,132,792
Market Cap
$3.10M
Dividend & Yield
--
52-Week Range
$0.197 - $1.79
P/E (TTM)
--
EPS (TTM)
-$7.16
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
SciSparc (SPRC) and Clearmind Medicine File Patent for New Eating Disorder Treatment CMND ...
4/25/2025 - GuruFocus
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel ...
4/25/2025 - GuruFocus
SciSparc announces collaboration with Clearmind Medicine
4/25/2025 - The Fly
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel ...
4/25/2025 - GuruFocus
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
4/25/2025 - Globe Newswire
Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Declines By 40.9%
4/18/2025 - Ticker Report
SciSparc announces resale of 61.21M shares by selling shareholders; shares down
3/25/2025 - Seeking Alpha - Healthcare
SciSparc announces resale of 61.21M shares by selling shareholders; shares down
3/25/2025 - Seeking Alpha - Israel Stocks
SciSparc files to sell 61.21M ordinary shares for holders
3/25/2025 - TipRanks Financial Blog
SciSparc files to sell 61.21M ordinary shares for holders
3/25/2025 - The Fly
SciSparc Shares Are Soaring Monday: What's Going On?
3/10/2025 - Benzinga
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine ...
3/10/2025 - GuruFocus
SciSparc announces publication of patent via Clearmind collaboration
3/10/2025 - The Fly
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
3/10/2025 - Globe Newswire
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company ...
3/3/2025 - GuruFocus
SciSparc to sell MitoCareX to N2Off for $700,000
3/3/2025 - Seeking Alpha - Israel Stocks
SciSparc to sell MitoCareX to N2Off for $700,000
3/3/2025 - Seeking Alpha - Healthcare
SciSparc signs definitive agreement to sell MitoCareX to N2OFF
3/3/2025 - The Fly
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
3/3/2025 - Globe Newswire
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into ...
2/27/2025 - GuruFocus
SciSparc extends $2M loan to support AutoMax growth
2/27/2025 - The Fly
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles
2/27/2025 - Globe Newswire
N2OFF signs definitive agreement to acquire MitoCareX from SciSparc
2/26/2025 - The Fly
SciSparc Ltd. Reaches Favorable Lawsuit Settlement, Secures Cash Compensation and IP Rights
2/18/2025 - TipRanks Financial Blog
SciSparc Reveals Favorable Cash Settlement In Lawsuit, Shares Up
2/18/2025 - RTT News - Momentum Stocks
Income Statement
Total Revenue (TTM)
$1.75M
EBITDA (TTM)
-$5.89M
EBIT (TTM)
-$6.33M
Net Income (TTM)
-$5.68M
Balance Sheet
Total Assets (Q)
$10.48M
Total Debt (Q)
$64.00K
Total Liabilities (Q)
$1.83M
Book Value Per Share (Q)
$1.93
Cash Flow
Cash from Operations (TTM)
-$4.85M
Cash from Investing (TTM)
$54.00K
Cash from Financing (TTM)
$2.97M
Net Change in Cash (TTM)
-$1.83M
Filings
Filing Date
Monday, November 4, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Beginning of April (est)
Price History
Loading...
Beta
1.24
7-Day Total Return
3.25%
30-Day Total Return
-25.49%
60-Day Total Return
-36.72%
90-Day Total Return
3.02%
Year to Date Total Return
-28.83%
1-Year Total Return
-78.83%
2-Year Total Return
-98.49%
3-Year Total Return
-99.63%
5-Year Total Return
--
52-week Low
Dec 23, 2024 - $0.197
52-week High
Jan 06, 2025 - $1.79
Valuation
Market Cap
$3.10M - Nano Cap
Enterprise Value
$1.87M
Price/Sales (TTM)
0.33
Price/Book (Q)
0.15
Dividends and Shares
Shares Outstanding
2.02M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
scisparc.com
Phone Number
972 7 334 47180
Address
Tower A
2nd Floor - 20 Raul Wallenberg Street
Tel Aviv, 6971916
Country
Israel
Year Founded
2004
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and... more
NASDAQ 04/28/2025 4:00PM Eastern Quotes delayed